Lymphomas News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Checkpoint Inhibition for Non-Hodgkin and Hodgkin Lymphomas - Cancer Therapy Advisor



Cancer Therapy Advisor
 
Checkpoint Inhibition for Non-Hodgkin and Hodgkin Lymphomas 
Cancer Therapy Advisor
Classical Hodgkin lymphoma (cHL) has a cure rate of about 75% with standard chemotherapy. Its nearly universal genetic alterations, furthermore, likely contribute to its unique sensitivity to PD-1 blockade. Most non-Hodgkin lymphomas (NHL) do not ...

 


NCCN Updates Guidelines for B-Cell Lymphomas - Journal of Clinical Pathways



Journal of Clinical Pathways
 
NCCN Updates Guidelines for B-Cell Lymphomas 
Journal of Clinical Pathways
The National Comprehensive Cancer Network (NCCN) released updated guidelines for a variety of B-cell lymphomas, including follicular lymphoma, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL). For ...

 


Checkpoint inhibitors may have role posttransplant for aggressive B-cell lymphoma - Healio



Checkpoint inhibitors may have role posttransplant for aggressive B-cell lymphoma 
Healio
SALT LAKE CITY ? Preliminary data have suggested the potential role for immune checkpoint inhibitors in the posttransplant setting among patients with relapsed/ large B-cell lymphomas, according to a presenter at the BMT Tandem Meetings. Immune ...

 


Lymphoma treatment outcomes just as good for people with HIV - aidsmap



Lymphoma treatment outcomes just as good for people with HIV 
aidsmap
254 achieved complete remission after the first course of treatment (127 with DLBCL, 91 with Burkitt's lymphoma, 29 with plasmablastic lymphoma and seven with other non-classifiable B-cell lymphomas). This group represented just under two-thirds (63 ...

and more » 


Affimed Reports New Data for AFM13 from Two Separate Clinical Trials in Hodgkin and CD30-Positive Lymphomas - GlobeNewswire (press release)



CNA Finance
 
Affimed Reports New Data for AFM13 from Two Separate Clinical Trials in Hodgkin and CD30-Positive Lymphomas 
GlobeNewswire (press release)
Heidelberg, Germany, February 1, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today reported additional preliminary patient data from two ...
Updated data on Affimed's AFM13 shows 89% response rate in HL patients; shares up 28% Seeking Alpha

all 28 news articles » 


B-Cell Lymphomas Market Overview, Development, Diagnosis and ... - The Financial



B-Cell Lymphomas Market Overview, Development, Diagnosis and ... 
The Financial
B-Cell Lymphomas ? Market Insights, Epidemiology and Market Forecast ? 2027?? report provides a detailed analysis of the B-Cell Lymphomas epidemiology and market outlook for the 7MM.United States, EU5 (Germany, France, Italy, Spain, and the United ...

and more » 


Peripheral T-Cell Lymphomas (PTCL) Pipeline Analysis 2018 - Facts of Week



Peripheral T-Cell Lymphomas (PTCL) Pipeline Analysis 2018 
Facts of Week
Peripheral T-Cell Lymphomas (PTCL)- Competitive Landscape, Pipeline and Market Analysis, 2017, report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the ...

and more » 


B-Cell Lymphomas Market Analysis, Market Size, Application Analysis, Regional Outlook, Competitive Strategies and ... - The Financial



B-Cell Lymphomas Market Analysis, Market Size, Application Analysis, Regional Outlook, Competitive Strategies and ... 
The Financial
?B-Cell Lymphomas- Pipeline Insight, 2018?offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across B-Cell Lymphomas development. The report provides detailed coverage of the pipeline landscape ...

 


Salvage therapies may improve survival outcomes of lymphoma patients after allo-HCT - Lymphoma Hub



Lymphoma Hub
 
Salvage therapies may improve survival outcomes of lymphoma patients after allo-HCT 
Lymphoma Hub
Allogeneic hematopoietic cell transplant (allo-HCT) remains a treatment option for relapsed/refractory (R/R) lymphoma patients who are ineligible for or relapse after autologous HCT. A retrospective study by Narendranath Epperla et al assessed the ...

 


'Encouraging' results with JCAR017 for relapsed, refractory lymphoma - Healio



'Encouraging' results with JCAR017 for relapsed, refractory lymphoma 
Healio
High-risk patients with relapsed and refractory diffuse large B-cell lymphoma who received JCAR17 chimeric antigen receptor T-cell therapy had an overall response rate of 80% and a complete remission rate of 55%, according to results of a phase 1 trial ...